Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 6/20 | 0.43 |
| ▸ | DYRK3 | O43781 | 2/20 | 0.43 |
| ▸ | CDK2 | P24941 | 2/20 | 0.43 |
| ▸ | GSK3B | P49841 | 2/20 | 0.43 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.43 |
| ▸ | PIM3 | Q86V86 | 2/20 | 0.43 |
| ▸ | MINK1 | Q8N4C8 | 2/20 | 0.43 |
| ▸ | PRKD2 | Q9BZL6 | 2/20 | 0.43 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.43 |
| ▸ | SGK2 | Q9HBY8 | 2/20 | 0.43 |
| ▸ | STK17A | Q9UEE5 | 2/20 | 0.43 |
| ▸ | CDK1 | P06493 | 1/20 | 0.43 |
| ▸ | CDK7 | P50613 | 1/20 | 0.43 |
| ▸ | CAMK2G | Q13555 | 1/20 | 0.43 |
| ▸ | MARK2 | Q7KZI7 | 1/20 | 0.43 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.43 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.43 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.39 |
| ▸ | ELANE | P08246 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2128792 | 0.92 | DYRK3 (0.52) | DYRK3CDK2GSK3BCDK5PIM3 | |
| Hydrochloric Acid SCHEMBL3190961 | 0.79 | EGLN1 (0.48) | ALKDYRK3CDK2GSK3BCDK5 | |
| Hydrochloric Acid SCHEMBL3192123 | 0.77 | EGLN1 (0.49) | ALKDYRK3CDK2GSK3BCDK5 | |
| SCHEMBL2600368 | 0.76 | HCRTR1 (0.44) | DYRK3CDK2GSK3BCDK5PIM3 | |
| SCHEMBL2130483 | 0.75 | CDK5 (0.55) | ALKDYRK3CDK2GSK3BCDK5 | |
| SCHEMBL4060329 | 0.75 | CCNE1 (0.46) | CDK2GSK3BCDK5CDK1HCRTR1 | |
| Hydrochloric Acid SCHEMBL3192660 | 0.74 | EGLN1 (0.48) | ALKDYRK3CDK2GSK3BCDK5 | |
| SCHEMBL7380783 | 0.73 | GABRA1 (0.67) | KDM4EALDH1A1MAPTSMN1; SMN2HPGD | |
| SCHEMBL941764 | 0.73 | CDK1 (0.48) | DYRK3CDK2GSK3BCDK5PIM3 | |
| SCHEMBL29800427 | 0.71 | CA12 (0.56) | MEN1ALDH1A1MAPTRAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1667990-A2 | NEW COMPOUNDS | AstraZeneca AB (SE) | 2006-06-14 | — | — | EP | claimed |
| WO-2005027823-A2 | 3-HETEROCYCLYL-INDOLE DERIVATIVES AS INHIBITORS OF GLYCOGEN SYNTHASE KINASE-3 (GSK-3) | ASTRAZENECA AB (SE) | 2005-03-31 | — | — | WO | claimed |
| US-7683067-B2 | 3-heterocyclyl-indole derivatives as inhibitors of glycogen synthase kinase-3 (GSK-3) | ASTRAZENECA AB (SE) | 2010-03-23 | — | — | US | disclosed |
| US-20080275041-A1 | 3-Heterocyclyl-Indole Derivatives as Inhibitors of Glycogen Synthase Kinase-3 (Gsk-3) | ASTRAZENECA AB (SE) | 2008-11-06 | — | — | US | disclosed |
| EP-1667990-A2 | NEW COMPOUNDS | AstraZeneca AB (SE) | 2006-06-14 | — | — | EP | disclosed |
| WO-2005027823-A2 | 3-HETEROCYCLYL-INDOLE DERIVATIVES AS INHIBITORS OF GLYCOGEN SYNTHASE KINASE-3 (GSK-3) | ASTRAZENECA AB (SE) | 2005-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275041-A1 | 3-Heterocyclyl-Indole Derivatives as Inhibitors of Glycogen Synthase Kinase-3 (Gsk-3) | GSK3B, GSK3A, GSKIP | ALK 1581/4885DYRK3 108/4885CDK2 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.